X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs WOCKHARDT LTD. - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE WOCKHARDT LTD. STRIDES PHARMA SCIENCE/
WOCKHARDT LTD.
 
P/E (TTM) x 51.2 -19.1 - View Chart
P/BV x 1.1 2.0 54.9% View Chart
Dividend Yield % 0.4 0.0 22,959.3%  

Financials

 STRIDES PHARMA SCIENCE   WOCKHARDT LTD.
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
WOCKHARDT LTD.
Mar-18
STRIDES PHARMA SCIENCE/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,1471,012 113.3%   
Low Rs642532 120.8%   
Sales per share (Unadj.) Rs317.2355.9 89.1%  
Earnings per share (Unadj.) Rs7.8-60.3 -13.0%  
Cash flow per share (Unadj.) Rs25.1-46.8 -53.6%  
Dividends per share (Unadj.) Rs2.000.01 20,000.0%  
Dividend yield (eoy) %0.20 17,255.4%  
Book value per share (Unadj.) Rs274.3257.8 106.4%  
Shares outstanding (eoy) m89.50110.63 80.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.2 130.0%   
Avg P/E ratio x114.0-12.8 -890.6%  
P/CF ratio (eoy) x35.7-16.5 -216.3%  
Price / Book Value ratio x3.33.0 109.0%  
Dividend payout %25.50 -153,677.2%   
Avg Mkt Cap Rs m80,05885,379 93.8%   
No. of employees `0002.56.3 40.1%   
Total wages/salary Rs m4,3419,371 46.3%   
Avg. sales/employee Rs Th11,325.86,295.0 179.9%   
Avg. wages/employee Rs Th1,731.41,498.3 115.6%   
Avg. net profit/employee Rs Th280.1-1,066.3 -26.3%   
INCOME DATA
Net Sales Rs m28,39439,369 72.1%  
Other income Rs m9411,202 78.2%   
Total revenues Rs m29,33440,571 72.3%   
Gross profit Rs m3,96518 21,668.9%  
Depreciation Rs m1,5401,495 103.0%   
Interest Rs m1,9622,555 76.8%   
Profit before tax Rs m1,403-2,830 -49.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-3,582 12.2%   
Tax Rs m97257 37.9%   
Profit after tax Rs m702-6,669 -10.5%  
Gross profit margin %14.00 30,044.6%  
Effective tax rate %6.9-9.1 -76.3%   
Net profit margin %2.5-16.9 -14.6%  
BALANCE SHEET DATA
Current assets Rs m24,83633,796 73.5%   
Current liabilities Rs m18,99326,917 70.6%   
Net working cap to sales %20.617.5 117.8%  
Current ratio x1.31.3 104.1%  
Inventory Days Days7179 89.4%  
Debtors Days Days11389 127.1%  
Net fixed assets Rs m34,28939,664 86.4%   
Share capital Rs m895553 161.8%   
"Free" reserves Rs m23,65127,968 84.6%   
Net worth Rs m24,54628,522 86.1%   
Long term debt Rs m15,51321,731 71.4%   
Total assets Rs m65,43781,620 80.2%  
Interest coverage x1.7-0.1 -1,595.1%   
Debt to equity ratio x0.60.8 83.0%  
Sales to assets ratio x0.40.5 90.0%   
Return on assets %4.1-5.0 -80.8%  
Return on equity %2.9-23.4 -12.2%  
Return on capital %6.9-7.7 -89.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,6979,807 160.1%   
Fx outflow Rs m7351,789 41.1%   
Net fx Rs m14,9628,019 186.6%   
CASH FLOW
From Operations Rs m1,871684 273.3%  
From Investments Rs m5,8266,302 92.4%  
From Financial Activity Rs m-10,157-7,695 132.0%  
Net Cashflow Rs m-2,615-664 393.8%  

Share Holding

Indian Promoters % 27.7 74.5 37.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 2.3 1,643.5%  
FIIs % 8.6 7.7 111.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 25.9 15.4 168.2%  
Shareholders   56,241 67,757 83.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; Energy & PSU Stocks Outperform(12:30 pm)

Stock markets in India are trading range-bound in the afternoon session. Among the sectoral indices, IT stocks and healthcare stocks are witnessing maximum selling pressure.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 14, 2018 12:44 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - FULFORD INDIA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS